Collegium Pharma (COLL) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update
March 7, 2018 4:01 PM ESTXtampza ER prescriptions grew by 37% in the fourth quarterFDA Approval of sNDA, including Comparative OxyContin Data in labelExpanded product portfolio by licensing rights to commercialize Nucynta franchiseRevenue growth and strong balance sheet provide cash runway into 2020 Conference call scheduled for today at 4:30 p.m. ET
CANTON, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the fourth quarter and year ended December 31, 2017 and provided a corporate update.Â
... More


